Company intelligence / Profile preview

Selene Therapeutics

Ownership: Private
Development stage: Preclinical

Overview

Selene Therapeutics is developing novel therapies for refractory epilepsy by targeting mitochondrial DHODH to regulate neuronal activity set points. Their approach has shown promise in preclinical models, but no clinical results have been reported yet.

Therapeutic areas: Neurology
Modalities: Small molecules
Industry: Biotech

Partnerships

FuturX BioAccelerator (J&J, Takeda, Orbimed Israel Partners, Bayer)Israeli Innovation AuthorityRMGP Biopharma Investment Fund

Beyond the preview

Go deeper on Selene Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Selene Therapeutics.

Explore the full profile